These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 23791944)

  • 1. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
    Schmitz KR; Bagchi A; Roovers RC; van Bergen en Henegouwen PM; Ferguson KM
    Structure; 2013 Jul; 21(7):1214-24. PubMed ID: 23791944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
    Schmiedel J; Blaukat A; Li S; Knöchel T; Ferguson KM
    Cancer Cell; 2008 Apr; 13(4):365-73. PubMed ID: 18394559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8.
    Li S; Kussie P; Ferguson KM
    Structure; 2008 Feb; 16(2):216-27. PubMed ID: 18275813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular view of anti-ErbB monoclonal antibody therapy.
    Leahy DJ
    Cancer Cell; 2008 Apr; 13(4):291-3. PubMed ID: 18394550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.
    Li S; Schmitz KR; Jeffrey PD; Wiltzius JJ; Kussie P; Ferguson KM
    Cancer Cell; 2005 Apr; 7(4):301-11. PubMed ID: 15837620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X; Weeks SD; Ameloot P; Callewaert N; Strelkov SV; Declerck PJ
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches.
    Farasat A; Rahbarizadeh F; Hosseinzadeh G; Sajjadi S; Kamali M; Keihan AH
    J Biomol Struct Dyn; 2017 Jun; 35(8):1710-1728. PubMed ID: 27691399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanobody Targeting of Epidermal Growth Factor Receptor (EGFR) Ectodomain Variants Overcomes Resistance to Therapeutic EGFR Antibodies.
    Tintelnot J; Baum N; Schultheiß C; Braig F; Trentmann M; Finter J; Fumey W; Bannas P; Fehse B; Riecken K; Schuetze K; Bokemeyer C; Rösner T; Valerius T; Peipp M; Koch-Nolte F; Binder M
    Mol Cancer Ther; 2019 Apr; 18(4):823-833. PubMed ID: 30824613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural insights into the non-inhibitory mechanism of the anti-EGFR EgB4 nanobody.
    Zeronian MR; Doulkeridou S; van Bergen En Henegouwen PMP; Janssen BJC
    BMC Mol Cell Biol; 2022 Mar; 23(1):12. PubMed ID: 35232398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope.
    Makabe K; Yokoyama T; Uehara S; Uchikubo-Kamo T; Shirouzu M; Kimura K; Tsumoto K; Asano R; Tanaka Y; Kumagai I
    Sci Rep; 2021 Mar; 11(1):5790. PubMed ID: 33707468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes.
    Padhi AK; Kumar A; Haruna KI; Sato H; Tamura H; Nagatoishi S; Tsumoto K; Yamaguchi A; Iraha F; Takahashi M; Sakamoto K; Zhang KYJ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34415295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Characterization of Nanobodies during Germline Maturation.
    Seidler CA; Kokot J; Fernández-Quintero ML; Liedl KR
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth.
    Roovers RC; Vosjan MJ; Laeremans T; el Khoulati R; de Bruin RC; Ferguson KM; Verkleij AJ; van Dongen GA; van Bergen en Henegouwen PM
    Int J Cancer; 2011 Oct; 129(8):2013-24. PubMed ID: 21520037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response with long-term memory triggered by amorphous aggregates of misfolded anti-EGFR V
    Golam Kibria M; Akazawa-Ogawa Y; Hagihara Y; Kuroda Y
    Eur J Pharm Biopharm; 2021 Aug; 165():13-21. PubMed ID: 33971271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor.
    Iacob RE; Chen G; Ahn J; Houel S; Wei H; Mo J; Tao L; Cohen D; Xie D; Lin Z; Morin PE; Doyle ML; Tymiak AA; Engen JR
    J Am Soc Mass Spectrom; 2014 Dec; 25(12):2093-102. PubMed ID: 25223306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crystal structures of a llama VHH antibody BCD090-M2 targeting human ErbB3 receptor.
    Eliseev IE; Yudenko AN; Vysochinskaya VV; Svirina AA; Evstratyeva AV; Drozhzhachih MS; Krendeleva EA; Vladimirova AK; Nemankin TA; Ekimova VM; Ulitin AB; Lomovskaya MI; Yakovlev PA; Bukatin AS; Knyazev NA; Moiseenko FV; Chakchir OB
    F1000Res; 2018; 7():57. PubMed ID: 30430004
    [No Abstract]   [Full Text] [Related]  

  • 18. The effect of subcellular localization on the efficiency of EGFR-targeted VHH photosensitizer conjugates.
    van Lith SAM; van den Brand D; Wallbrecher R; Wübbeke L; van Duijnhoven SMJ; Mäkinen PI; Hoogstad-van Evert JS; Massuger L; Ylä-Herttuala S; Brock R; Leenders WPJ
    Eur J Pharm Biopharm; 2018 Mar; 124():63-72. PubMed ID: 29274374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delineating the functional map of the interaction between nimotuzumab and the epidermal growth factor receptor.
    Tundidor Y; García-Hernández CP; Pupo A; Cabrera Infante Y; Rojas G
    MAbs; 2014; 6(4):1013-25. PubMed ID: 24759767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance.
    Bagchi A; Haidar JN; Eastman SW; Vieth M; Topper M; Iacolina MD; Walker JM; Forest A; Shen Y; Novosiadly RD; Ferguson KM
    Mol Cancer Ther; 2018 Feb; 17(2):521-531. PubMed ID: 29158469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.